AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03236779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
Study NCT02565225 — intervention group
Intervention type: BEHAVIORAL
Intervention: RheumaLive App use
Study NCT02981953 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioband Tricuspid
Description: The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAG
Description: Community Adherence Group
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UAG
Description: Urban Adherence Group
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UAG
Description: Urban Adherence Group
Study NCT04562883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) culture
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
Study NCT04221321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg
Study NCT04221321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg
Study NCT04221321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg
Study NCT04221321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet
Study NCT04221321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPA114
Description: RAPA114 tablet
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST-TRACK
Description: Prescription refill only
Study NCT02842749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
Study NCT00446082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study NCT02356848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Description: Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
Study NCT02356848 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current Practice (CP)
Description: this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
Study NCT01277484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 1. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model
Study NCT02019875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: P450 inducer
Study NCT02771782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine (SSI)
Study NCT02771782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDaP-IPV vaccine
Study NCT04391660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% sodium hypochlorite solution
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
Study NCT04391660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% sodium hypochlorite solution and 70% ethanol
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
Study NCT03424811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Health Intervention
Description: Mobile health intervention to promote healthy eating.
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Administered orally
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally
Study NCT04586920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally
Study NCT03031327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin 20µg/ml
Description: Lubricin 20µg/ml eye drops
Study NCT03031327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin 50µg/ml
Description: Lubricin 50µg/ml eye drops
Study NCT03031327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 0.18%
Description: Sodium hyaluronate (HA) 0.18% eye drops
Study NCT03580707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRV vs LEV in randomized double blinded, crossover fashion
Description: Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
Study NCT01768624 — intervention group
Intervention type: PROCEDURE
Intervention: dialysis, kidney transplant
Study NCT03114475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation
Description: CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
Study NCT03114475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
Study NCT03971474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT04422600 — intervention group
Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The investigators will then correlate that exposure with neurodevelopmental outcomes.
Study NCT01884142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Study NCT01255449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: 400 mcg by inhalation
Study NCT03290196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EXPAREL 1.3 % in 20 ML Injection
Description: EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
Study NCT02160509 — intervention group
Intervention type: DEVICE
Intervention: IPhone based realtime remote ultrasound interpretation
Study NCT04829773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: oral capsules
Study NCT04829773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: oral syrup
Study NCT02735161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
Study NCT02735161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Description: Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
Study NCT00954642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00247052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 50 mg bid versus placebo bid
Study NCT00247052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 100 mg per day for 14 days
Study NCT00247052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Study NCT02108561 — intervention group
Intervention type: OTHER
Intervention: Post Surgical Her2 testing
Description: Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
Study NCT03502265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otteroo
Description: Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study NCT02019875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: CYP3A4 and Pgp inhibitor in both intestine and liiver
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: feladilimab will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.
Study NCT01992185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Vitiligo
Description: Photocil for Vitiligo
Study NCT01992185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study NCT01043887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: single oral dose administration 10 mg ridaforolimus
Study NCT01458353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Description: Stapled anastomosis after ileocolonic resection
Study NCT01458353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Description: Handsewn anastomosis after ileocolonic resection
Study NCT02071030 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Third molar removal
Description: Surgically removing the third molar in the lower jaw
Study NCT02019875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: CYP3A4 inhibitor in intestine
Study NCT02019875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03274518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis
Description: Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration
Study NCT03274518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Hemodiafiltration
Description: Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis.
Study NCT00147303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042
Study NCT00692419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom management nurse intervention
Description: A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
Study NCT04062383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
Study NCT00403845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00954642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNRP1685A
Description: Escalating intravenous dose
Study NCT00954642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT00692419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback intervention
Description: Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
Study NCT03515642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: Physical Training
Study NCT03515642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT group
Description: Physical Training
Study NCT03684382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeW-I group
Description: A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
Study NCT01628965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study NCT02736565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
Description: Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered.
Study NCT04126200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.
Study NCT01423266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 12-week supervised weight loss intervention
Description: Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
Study NCT01423266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 12-week supervised weight loss intervention
Description: Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
Study NCT01029847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
Study NCT01029847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
Study NCT00527904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
Study NCT00527904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
Study NCT00403845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00403845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00028600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC >= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC > 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
Study NCT00028600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ cells
Description: 2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant